Sanford Applied Biosciences (SAB) has developed the world's first large animal platform technology to produce fully human antibodies, both monoclonal and polyclonal, using the latest advances in gene engineering and transfer to produce new biopharmaceuticals that help fight disease. The antibodies generated in this unique system have been shown to have high diversity and high affinity compared to other genetically engineered animal systems.
The company, headquartered in Sioux Falls, South Dakota is a part of Sanford Health, the largest rural health organization in the United States. SAB has developed a line of cattle that produce fully human antibodies as part of its diversitAbTM technology. SAB's patented process involves inserting human genes for antibody production into cattle and inactivating the native antibody genes. The genetically engineered cattle, known as Tc (Transchromosomal) Bovine™ are used to produce plasma derived polyclonal (diversipAbsTM) and recombinant human antibodies (diversiMabsTM). These antibodies are developed for treatment of human diseases such as cancer, autoimmune disorders, inflammation, infectious diseases and others.
SAB is seeking collaboration partners with antigen technologies to co-develop antibody candidates. The diversitAbTM system is also used to produce targeted human antibody standards and reagents for quality control and immunogenicity assays for other drugs and biologics.
If you have questions or would like more information about Sanford Applied Biosciences, you can contact us through the following channels.
2301 E 60th Street N
Sioux Falls, SD 57104
Phone: (605) 312-6170
Fax: (605) 312-6071
Map to Corporate Office
1/14/2013 - Sanford Health acquires international bio-tech company Hematech, Inc.